Ophthalmology

S2E10: 'Meet the Innovators' - Andrew Bartynski, co-founder, AesculaTech

S2E10: 'Meet the Innovators' - Andrew Bartynski, co-founder, AesculaTech

“Reverse Chocolate for Dry Eye” Los Angeles-based start-up, AesculaTech, Inc., is developing a platform of temperature-responsive smart materials, including their first product, AesculaGel, a punctal plug for the treatment of dry eye syndrome that is applied as a liquid then solidifies at body temperature and blocks tear ducts. In this interview, co-founder Andrew Bartynski talks about his experiences in getting the company and its technology where it is and what’s next for AesculaTech.

A Look Back at a Year 'In MedTech History'

A Look Back at a Year 'In MedTech History'

This week we celebrate the one-year anniversary of MedTech Strategist’s Community Blog, and the In MedTech History series, with a powerful quote that suits today’s thriving, evolving, innovative, life-saving medical device industry perfectly:

"If I have seen further it is by standing on the shoulders of Giants." – Sir Isaac Newton, 1675

'In MedTech History' - Ophthalmic Implants - Part 2

'In MedTech History' - Ophthalmic Implants - Part 2

We continue our conversation about the future of the “eye-catching” ophthalmic device space with Andrew Iwach, MD, Executive Director of the Glaucoma Center of San Francisco, and clinical spokesperson for the American Academy of Ophthalmology. In this installment, we take a look at recent advancements in cataract surgery, that promise to impact the vision of millions of patients worldwide, as well as important unmet clinical needs across ophthalmology.

'In MedTech History' - Ophthalmic Implants - Part 1

'In MedTech History' - Ophthalmic Implants - Part 1

In this installment of IMH, we take a look at the pioneering early work in intraocular lenses that laid the foundation for the remarkable devices on the market and under development today that are preserving and even restoring vision. We also discuss three important trends to watch in the ophthalmic implant space, according to Andrew Iwach, MD, Executive Director of the Glaucoma Center of San Francisco, and clinical spokesperson for the American Academy of Ophthalmology.